Perifosine: Preliminary Phase II data

Preliminary data from an ongoing Phase II trial in 26 patients showed that twice-daily 50 mg perifosine for 28 days led to a partial response in 4 of 4 patients with chronic lymphocytic leukemia (CLL)...